Fonte: Brazilian Journal of Pharmaceutical Sciences. Nome do evento: Pharmaceutical Science and Technology Meeting of the Faculty of Pharmaceutical Sciences. Unidade: FM
Assuntos: MELANOMA, MUTAÇÃO GENÉTICA, RESUMOS (EVENTOS)
ABNT
TORTELLI JUNIOR, Tharcísio Citrângulo e CHAMMAS, Roger e CHELLAPPAN, Srikumar. Interaction between braf inhibitor PLX-4720 and CDKS inhibitors can sensitize melanoma cells with braf V600E mutation. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2013APA
Tortelli Junior, T. C., Chammas, R., & Chellappan, S. (2013). Interaction between braf inhibitor PLX-4720 and CDKS inhibitors can sensitize melanoma cells with braf V600E mutation. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Medicina, Universidade de São Paulo.NLM
Tortelli Junior TC, Chammas R, Chellappan S. Interaction between braf inhibitor PLX-4720 and CDKS inhibitors can sensitize melanoma cells with braf V600E mutation. Brazilian Journal of Pharmaceutical Sciences. 2013 ; 49 94.[citado 2024 nov. 01 ]Vancouver
Tortelli Junior TC, Chammas R, Chellappan S. Interaction between braf inhibitor PLX-4720 and CDKS inhibitors can sensitize melanoma cells with braf V600E mutation. Brazilian Journal of Pharmaceutical Sciences. 2013 ; 49 94.[citado 2024 nov. 01 ]